PLANO, Texas, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, will join medtech industry leaders and innovators around the world in exhibiting at the MD&M Minneapolis Exposition from Oct. 10 – 11, 2023, at the Minneapolis Convention Center.
Attendees are invited to visit Integer at booth #3011 to learn more about Integer’s range of innovative end-to-end medical device design, development and manufacturing solutions.
During MD&M Minneapolis, the Integer team will be on hand to discuss how we blend our technology, expertise and resources to amplify our customers’ innovation and increase speed to market, as well as specific capabilities and solutions to enable cardio & vascular, cardiac rhythm management, and neuromodulation products.
At the Expo, Integer will be specifically highlighting new advances in miniaturization for implantable battery technology. This extends to a new micro-coin cell form factor supporting miniaturization for novel therapeutic and diagnostic devices. Available in Li Ion Gen 3 rechargeable or CFx primary cell chemistries, these batteries can be as small as 0.0047 cc – 3 mm x 0.7 mm. Its hermetic design for implantable devices is backed by Integer’s reliable field-tested technologies.
“Through Integer’s product portfolio and end-to-end development and manufacturing capabilities, we provide innovative, high-quality medical device technologies that exceed customer expectations,” said Jim Stephens, President, CRM&N. “Our deep expertise, flexible approach, vertically integrated supply chain and global footprint enable us to support our customers every step of the way.”
Learn more about Integer at www.integer.net.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. Integer provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the company develops batteries for high-end niche applications in energy, military and environmental markets. The company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
Investor Relations: | Media Relations: |
Andrew Senn | Kelly Butler |
This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
763.951.8312 | 214.618.4216 |
Last Trade: | US$143.28 |
Daily Change: | 1.84 1.30 |
Daily Volume: | 229,024 |
Market Cap: | US$4.810B |
October 24, 2024 September 23, 2024 August 22, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load